Piramal signs PET agent deal with Ci-Co Healthcare

Piramal Imaging has entered into a strategic partnership with Ci-Co Healthcare.

The deal includes an exclusive licensing agreement for Ci-Co Healthcare to obtain market authorization from the Korean Health Authorities and commercialize Piramal's PET amyloid imaging agent F-18 florbetaben in South Korea.

Ci-Co has assigned the manufacturing and supply of the agent to DuChemBio, a radiopharmacy network in South Korea.

Page 1 of 435
Next Page